Login / Signup

Real-world utilization of SARS-CoV-2 serological testing in RNA positive patients across the United States.

Carla V Rodriguez-WatsonNatalie E SheilsAnthony M LouderElizabeth H EldridgeNancy D LinBenjamin D PollockJennifer L GatzShaun J GrannisRohit VashishtKanwal GhauriGina ValoAloka G ChakravartyTamar LaskyMary JungStephen L LovellJacqueline M MajorCarly KabelacCamille KnepperSandy LeonardPeter J EmbiWilliam G JenkinsonReyna KleshOmai B GarnerAyan PatelLisa DahmAiden BarinDan M CooperTom AndriolaCarrie L ByingtonBridgit O CrewsAtul J ButteJeff D Allen
Published in: PloS one (2023)
Our results inform the underlying context of serotesting during the first year of the COVID-19 pandemic and differences observed between claims and EHR data sources-a critical first step to understanding the real-world accuracy of serological tests. Incomplete reporting of race/ethnicity data and a limited ability to link test manufacturer data, lab results, and clinical data challenge the ability to assess the real-world performance of SARS-CoV-2 tests in different contexts and the overall U.S. response to current and future disease pandemics.
Keyphrases
  • sars cov
  • electronic health record
  • big data
  • end stage renal disease
  • chronic kidney disease
  • respiratory syndrome coronavirus
  • data analysis
  • health insurance
  • deep learning
  • current status
  • drug induced